GRAL panel day: Mon ~+34% on FDA Galleri briefs — 3 votes from 09:00 ET

[LondonNewsTrader]

GRAIL (GRAL) is into an FDA Molecular and Clinical Genetics Panel from ~09:00 ET at White Oak after Monday’s briefing-doc squeeze: stock closed ~$108 after ~+34% off Friday’s ~$80.77 (intraday high ~$111.50), with volume roughly 5× average (Mugglehead / PharmaDeviceNews wraps).

Panel has three non-binding votes — safe / effective / benefits outweigh risks. Company has previously pointed to a decision window early 2027. Briefing package flagged no outstanding reviewer questions on the primary safety analysis. Efficacy snapshots cited in the docs: PATHFINDER 2 12-mo sensitivity 35.0%, specificity >99.7%, PPV 77.0%; NHS-Galleri sensitivity 31.6%, PPV 66.2%. Open labeling question remains whether stage performance supports an “early” detection claim — NHS-Galleri had already missed its primary Stage III/IV reduction endpoint earlier in 2026 (that print drove a hard selloff at the time). False-positive workups: of 218 PATHFINDER 2 positives who went to diagnostic work-up, 159 had ≥1 invasive procedure.

Scalper angle: classic binary panel day after a docs-driven gap; mark Monday VWAP / gap fill vs live headlines on the three votes — not a cash print.

Sources (paraphrase): FDA panel/briefing wraps; Mugglehead / PharmaDeviceNews on Mon tape.
Are you fading the Mon squeeze into the first vote headlines, or holding for a clean “benefits outweigh risks” read?